Please ensure Javascript is enabled for purposes of website accessibility

Repligen Bucks Industry Trend, Increases Full-Year 2020 Guidance

By Maxx Chatsko - May 6, 2020 at 3:40PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The bioprocess equipment leader didn't see a slowdown from the coronavirus pandemic, while expected headwinds in a major business unit failed to materialize.

Based on the simple facts that Repligen (RGEN 1.65%) generated 65% of full-year 2019 revenue from customers engaged in clinical trials and many clinical trials have been delayed due to the coronavirus pandemic, I told investors the business could face a temporary slowdown this year. So much for that caution. 

The bioprocess equipment leader not only delivered record quarterly revenue in the first three months of 2020, but also decided to increase full-year 2020 earnings guidance while keeping revenue expectations intact. That's a striking departure from the industry trend of withdrawing full-year 2020 guidance in response to the uncertainty created by the global coronavirus crisis. 

If it holds true, then the reliable growth stock deserves a closer look. Here's what investors need to know about Repligen's first-quarter 2020 operating results.

A woman pumping her fist in excitement as she sits with her laptop.

Image source: Getty Images.

By the numbers

Repligen's growth engine remains red hot. The business grew first-quarter 2020 revenue 25% from the year-ago period to a record $76 million. It did so while expanding gross margin to 58%, up from less than 56% in Q1 2019.

The performance was bolstered by a handful of surprises. When Repligen issued initial full-year 2020 guidance, investors were disappointed by its relative weakness. It now appears management was a little too conservative with initial expectations. 

For example, the company was surprised by the overnight rise of gene therapy customers in 2019 and figured the growth would fade somewhat this year, but gene therapy demand remained strong in Q1 2020. Similarly, the company's chromatography and filtration franchises (containing products used to purify biologic molecules) maintained momentum into this year. 

The biggest surprise was Repligen's protein business (proteins are packed into chromatography columns and other purification products), which was responsible for 24% of total revenue last year. Initially expected to weigh on overall growth in 2020, the segment performed above expectations. It all helped to drive a solid first-quarter performance. 

Metric

Q1 2020

Q1 2019

Change

Revenue 

$76.1 million

$60.6 million

25%

Gross margin

58%

55.7%

230 basis points

Operating income

$11.9 million

$11.2 million

6%

Net income

$9.8 million

$8.0 million

22%

Earnings per share (EPS)

$0.19

$0.18

5%

Data source: Press release.

Although Repligen acknowledged the uncertainty relating to the coronavirus pandemic, it doesn't expect the global health crisis to have severe negative consequences. The company decided to maintain full-year 2020 revenue guidance and increase expectations across a range of profitability metrics. 

Gross margin is now expected to be at least 56%, up from prior expectations of at least 55%. New projections for operating income and net income represent increases of 4% and 3%, respectively, compared to initial full-year 2020 guidance. The new expectations also compare favorably to Repligen's performance last year. 

Metric

Full-Year 2020 Guidance

Full-Year 2019 Actual

Change

Revenue 

$309 million to $319 million

$270 million

14% to 18%

Gross margin

56% to 57%

56%

Flat to 100 basis points

Operating income

$52 million to $56 million

$36 million

44% to 55%

Net income

$34.5 million to $37.5 million

$21.4 million

61% to 75%

EPS

$0.65 to $0.70

$0.44

48% to 59%

Data sources: Press release and SEC filing.

Considering clinical trial activities were responsible for 65% of total revenue in 2019, the fact Repligen expects no slowdown in light of delayed clinical trials across the industry is somewhat surprising. 

On the one hand, the company's bioprocess equipment is in high demand right now to support the development of dozens of treatment candidates for COVID-19 and vaccine candidates for the SARS-CoV-2 virus. 

On the other hand, any surges in orders related to the coronavirus pandemic could be temporary. Most drug candidates being studied to respond to the coronavirus pandemic are unlikely to be commercialized, as is the case for most drug candidates. But perhaps Repligen's unique position in the drug development and drug manufacturing processes can continue to provide momentum. 

After all, there will be tremendous pressure to manufacture millions -- or billions -- of doses of successful treatments and vaccines in a very short time frame. Integrating the company's products into the production processes of even one or two commercialized products addressing the global health crisis could provide significant tailwinds.

Well positioned for long-term success

Repligen reported strength from existing customers and perhaps a handful of temporary new ones racing to respond to the coronavirus pandemic in the first quarter of 2020. Those trends are allowing management to remain optimistic about a solid year of operations. Given the value provided by the company's bioprocess products, which are required to manufacture biologic drugs for clinical trials and commercial production runs, investors should expect momentum to continue for the foreseeable future.

Maxx Chatsko owns shares of Repligen. The Motley Fool recommends Repligen. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Repligen Corporation Stock Quote
Repligen Corporation
RGEN
$255.51 (1.65%) $4.16

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.